drugset

drugset / Trial / NCT00073125

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

NCT00073125 ↗

Phase 2 Completed 103 enrolled Abbott

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.

Timeline

Start: 2003-05
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-510	Peptide	—	—

Indications